Tafasitamab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Tafasitamab |
| DrugBank ID | DB15044 |
| Brand Names (EU) | Minjuvi |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.71% |
Approved Indication (EMA)
Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | drug-induced osteoporosis | 98.71% | DL |
| 2 | severe nonproliferative diabetic retinopathy | 97.34% | DL |
| 3 | diabetic retinopathy | 95.40% | DL |
| 4 | HER2 positive breast carcinoma | 94.51% | DL |
| 5 | psoriasis | 94.03% | DL |
| 6 | progesterone-receptor positive breast cancer | 93.00% | DL |
| 7 | normal breast-like subtype of breast carcinoma | 93.00% | DL |
| 8 | breast tumor luminal A or B | 92.91% | DL |
| 9 | progesterone-receptor negative breast cancer | 92.67% | DL |
| 10 | pityriasis lichenoides | 92.29% | DL |
| 11 | acne (disease) | 89.57% | DL |
| 12 | dermatitis | 89.32% | DL |
| 13 | ulcerative colitis (disease) | 88.74% | DL |
| 14 | congenital hypotrichosis with juvenile macular dystrophy | 88.57% | DL |
| 15 | neonatal dermatomyositis | 88.10% | DL |
| 16 | parapsoriasis | 87.99% | DL |
| 17 | amyopathic dermatomyositis | 87.58% | DL |
| 18 | acrodermatitis chronica atrophicans | 87.46% | DL |
| 19 | acne keloid | 87.36% | DL |
| 20 | diabetic cataract | 87.30% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.